Magda Chlebus is Executive Director Scientific & Regulatory Affairs at the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing the R&D-based pharmaceutical industry in Europe. Magda and her team are in charge of following policy and legislative developments that influence the research and regulatory environments for the healthcare industry in Europe. This includes public private collaborations (inter alia the Innovative Medicines Initiative and Innovative Health Initiative), enabling and sensitive technologies and the interface between new science and technology and regulation. She joined EFPIA in 1995. Her experience covers public and government affairs mainly at EU level, on a range of legislative and non-legislative files in the area of research, development and access to medicines and enabling technologies. Magda, a Polish national, holds a Master Degree in Applied Linguistics from the University of Warsaw.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 40 leading pharmaceutical companies and a growing number of small and medium-sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
Emer Cooke is the Executive Director of the European Medicines Agency, based in Amsterdam. She also holds the role of Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA). Previously, she was the Director responsible for all medical product-related regulatory activities at the World Health Organization in Geneva between November 2016 and November 2020. Ms. Cooke is a pharmacist with Masters degrees in Science and Business Administration from Trinity College Dublin. She has over 30 years' experience in international regulatory affairs and held management positions at the European Medicines Agency as Head of Inspections and Head of International Affairs respectively from 2002 until 2016. From September 1998 to July 2002, she worked in the Pharmaceuticals unit of the European Commission, where intra-alia, she was responsible for international collaboration, EU enlargement and the orphan medicines regulation.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
Prof. Dr. Christian Drosten studied medicine in Frankfurt am Main/Germany. He received his doctoral degree in 2003 with a thesis on high-throughput testing of blood donors for HBV and HIV-1. From June 2000, Drosten joined the virology department at Bernhard Nocht Institute for Tropical Medicine in Hamburg. His group focused on virus discovery and molecular diagnostics of tropical viral diseases. From 2007, Drosten became full professor and chair at the Institute of Virology at University of Bonn Medical Center. In 2017, he moved to Charité University Medicine in Berlin, where he is currently the Director of the Institute of Virology. He was a member of the German Ministry of Health's International Advisory Board on Global Health from 2017-2019. Drosten co-discovered the SARS coronavirus (SARS-CoV), for which he developed the first diagnostic tests in 2003. He worked on Middle East respiratory syndrome coronavirus (MERS-CoV) for which he resolved many aspects of the natural history of disease in humans and animals. In January 2020, his team developed the first SARS-CoV-2 RT-PCR test that was approved by the WHO and globally applied. His subsequent work focused on characterizing essential disease traits and diagnostic approaches in COVID-19. During the pandemic, he has been consulting German federal and state authorities and was appointed to the European Commission's advisory panel on Covid-19.